Trevena

Trevena, Inc. engages in the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Trevena, Inc. is a biopharmaceutical company, which focuses on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.

TRV045 demonstrated a favorable tolerability profile with no reported SAEs and no lymphopenia

Trevena Announces Completion of Phase 1 Study for TRV045, Novel S1P Receptor Modulator

OLINVYK commercialization progresses with Vizient contract and receipt of CMS outpatient pass-through reimbursement

Trevena Reports Third Quarter 2022 Results and Provides Business Update

Company to host a Conference Call & Webcast at 8:00 a.m. ET Company to host a Conference Call & Webcast at 8:00 a.m. ET

Trevena to Release Third Quarter 2022 Financial Results on November 9, 2022

OLINVYK study demonstrated a statistically significant reduced impact on respiratory function compared to IV morphine, among elderly/overweight subjects

Trevena Announces OLINVYK Poster Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting

CHESTERBROOK, Pa., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the Company will present a corporate overview at the H.C. Wainwright Annual Global Investment Conference being held in-person and virtually September 12- 14, 2022, in New York.

Trevena to Participate at the H.C. Wainwright Annual Global Investment Conference

Trevena (TRVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Trevena (TRVN) a New Buy Stock

Trevena, Inc. (NASDAQ:TRVN ) Q2 2022 Earnings Conference Call August 11, 2022 8:00 AM ET Company Participants Barry Shin – Chief Financial Officer Carrie Bourdow – President and Chief Executive Officer Patty Drake – Chief Commercial Officer Mark Demitrack – Chief Medical Officer Conference Call Participants Doug Tsao – H.C. Wainwright Operator Greetings, and welcome to Trevena Inc. Second Quarter 2022 Earnings Conference Call.

Trevena, Inc's (TRVN) CEO Carrie Bourdow on Q2 2022 Results - Earnings Call Transcript

Trevena (TRVN) delivered earnings and revenue surprises of 18.18% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Trevena (TRVN) Reports Q2 Loss, Lags Revenue Estimates

OLINVYK post-approval strategy advances with positive topline cognitive function data and continued enrollment in VOLITION clinical outcomes study

Trevena Reports Second Quarter 2022 Results and Provides Business Update

Trevena to Release Second Quarter 2022 Financial Results on August 11, 2022

CHESTERBROOK, Pa., July 29, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) ("Trevena" or the "Company"), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the closing of its previously announced registered direct offering with a single healthcare-focused institutional investor for the purchase and sale of 1,800 shares of Series A convertible preferred stock (“Series A Preferred”) and 200 shares of Series B convertible preferred stock (“Series B Preferred”) and warrants exercisable to purchase up to an aggregate of 8,000,000 shares of common stock. Each share of preferred stock has a stated value of $1,000 per share and a conversion price of $0.25 per share. The shares of preferred stock issued in the offering are convertible into an aggregate of 8,000,000 shares of common stock. The warrants have an exercise price of $0.263 per share, will be exercisable beginning on the later of six months following the date of issuance and the effective date of a reverse stock split of the Company's common stock in an amount sufficient to permit the exercise in full of the warrants, subject to stockholder approval of the reverse stock split, and will expire five and one-half years following the date of issuance.

Trevena, Inc. Announces Closing of Registered Direct Offering of Preferred Stock

CHESTERBROOK, Pa., July 29, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) ("Trevena" or the "Company"), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor for the purchase and sale of 1,800 shares of Series A convertible preferred stock (“Series A Preferred”) and 200 shares of Series B convertible preferred stock (“Series B Preferred”) and warrants exercisable to purchase up to an aggregate of 8,000,000 shares of common stock in a registered direct offering. Each share of preferred stock has a stated value of $1,000 per share and a conversion price of $0.25 per share. The shares of preferred stock issued in the offering are convertible into an aggregate of 8,000,000 shares of common stock. The warrants have an exercise price of $0.263 per share, will be exercisable beginning on the later of six months following the date of issuance and the effective date of a reverse stock split of the Company's common stock in an amount sufficient to permit the exercise in full of the warrants, subject to stockholder approval of the reverse stock split, and will expire five and one-half years following the date of issuance. The closing of the offering is expected to occur on or about July 29, 2022, subject to the satisfaction of customary closing conditions.

Trevena, Inc. Announces Registered Direct Offering of Preferred Stock

OLINVYK demonstrated statistically significant reduced impact on neurocognitive functioning vs IV morphine on primary endpoint

Trevena Announces Positive Topline OLINVYK Cognitive Function Data and Provides General Business Update

CHESTERBROOK, Pa., June 14, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced a publication in Expert Review of Neurotherapeutics titled “A critical review of oliceridine injection as an IV opioid analgesic for the management of severe acute pain ” by Eugene R. Viscusi, M.D., Director of Acute Pain Management at Jefferson Health (DOI: https://doi.org/10.1080/14737175.2022.2072731).

Trevena Announces the Publication of an Expert Review on the Clinical Profile of OLINVYK® in Post-Operative Care

TDH Hlds

Can these penny stocks make gains this coming week? The post Best Penny Stocks to Buy Next Week?

Best Penny Stocks to Buy Next Week? 3 to Watch?

CHESTERBROOK, Pa., June 10, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President & CEO, and Mark Demitrack, M.D., Senior Vice President and Chief Medical Officer, will participate in a fireside chat at the JMP Securities Life Sciences Conference being held in New York on June 15 - 16, 2022.

Trevena to Participate at the JMP Securities Life Sciences Conference

Epizyme

NRX Pharmaceuticals

Spectrum Pharma

Penny stocks to watch under $1 right now The post Hot Penny Stocks Under $1 To Watch In June appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks Under $1 To Watch In June

CHESTERBROOK, Pa., May 18, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President & CEO and Barry Shin, CFO, will be participating in the H.C. Wainwright Global Investment Conference being held May 23 - 26, 2022.

Trevena to Present at the H.C. Wainwright Global Investment Conference

Trevena, Inc. (NASDAQ:TRVN ) Q1 2022 Earnings Conference Call May 11, 2022 8:00 AM ET Company Participants Barry Shin - Senior Vice President & Chief Financial Officer Carrie Bourdow - President & Chief Executive Officer Patty Drake - Chief Commercial Officer Mark Demitrack - Chief Medical Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Jason Butler - JMP Securities Douglas Tsao - H.C. Wainwright Operator Good morning and welcome to the Trevena First Quarter 2022 Earnings Conference Call.

Trevena, Inc. (TRVN) CEO Carrie Bourdow on Q1 2022 Results - Earnings Call Transcript

Trevena (TRVN) delivered earnings and revenue surprises of -11.11% and 96.94%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Trevena (TRVN) Reports Q1 Loss, Lags Revenue Estimates

OLINVYK refocused commercial strategy initiated mid-Q1

Trevena Reports First Quarter 2022 Results and Provides Business Update

Trevena to Release First Quarter 2022 Financial Results on May 11, 2022

Trevena (TRVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Trevena (TRVN) to Report a Decline in Earnings: What to Look Out for

OLINVYK showed a statistically significant reduced impact on respiratory function compared to IV morphine, among elderly/overweight subjects

Trevena Announces Results from Respiratory Physiology Study of Head-to-Head Comparison of OLINVYK® and IV Morphine in Elderly/Overweight Subjects

CHESTERBROOK, Pa., April 18, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced receipt of the first $15 million tranche from its royalty-based financing agreement with an affiliate of R-Bridge Healthcare Fund (the R-Bridge Financing).

News for Trevena Stock (TRVN)